Tumour specific promoters like α-fetoprotein (AFP) to target hepatocellular carcinoma (HCC) [7], prostate-specific antigen (PSA) to target prostate cancer [8] and others [9] have been used to suppress tumour growth. This evidence concerns the gene AFP and hepatocellular carcinoma.